In various tumor entities, both the overexpression of receptors and tyrosine kinases such as EGFR, HER2/neu and IGF-1R, the inhibition of tumor cell growth by kinase inhibitors and synergistic effects of combining these inhibitors with conventional chemotherapy were shown [22–25]. Here, ERBB2 is linked to neoplasm.